Merck and Novo Nordisk Join TransCelerate
TransCelerate BioPharma Inc. today announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization.
TransCelerate BioPharma announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization, bringing the total number of members to 23. In addition, TransCelerate has appointed Briggs Morrison, MD, Executive Vice President, Global Medicines Development at AstraZeneca, to the position of Chair of the Board of Directors. Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
